a, Schema of diverse growth patterns observable in CLL samples. b, Illustrative patient white blood count (WBC) dynamics over the period between diagnosis and start of treatment. c, Putative CLL drivers detected by analysis of whole-exome sequencing (WES) analysis of pre-treatment serial samples from 21 patients, with assigned growth patterns, IGHV status. Cancer cell fractions (CCF) of mutations are indicated.